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Abstract
 
Mice deficient in the adaptor Src homology 2 domain-containing leukocyte phosphoprotein of
76 kD
 
 (
 
SLP-76) exhibit a bleeding disorder and lack T cells. Linker for activation of T cells
(LAT)-deficient mice exhibit a similar T cell phenotype, but show no signs of hemorrhage.
Both SLP-76 and LAT are important for optimal platelet activation downstream of the collagen
receptor, GPVI. In addition, SLP-76 is involved in signaling mediated by integrin 
 
 
 
IIb
 
 
 
3. Be-
cause SLP-76 and LAT function coordinately in T cell signal transduction, yet their roles appear
to differ in hemostasis, we investigated in detail the functional consequences of SLP-76 and LAT
deficiencies in platelets. Previously we have shown that LAT
 
 
 
/
 
 
 
 platelets exhibit defective re-
sponses to the GPVI-specific agonist, collagen-related peptide (CRP). Consistent with this, we
find that surface expression of P-selectin in response to high concentrations of GPVI ligands is
reduced in both LAT- and SLP-76–deficient platelets. However, platelets from LAT
 
 
 
/
 
 
 
 mice,
but not SLP-76
 
 
 
/
 
 
 
 mice, aggregate normally in response to high concentrations of collagen
and convulxin. Additionally, unlike SLP-76, LAT is not tyrosine phosphorylated after fibrino-
gen binding to integrin 
 
 
 
IIb
 
 
 
3, and collagen-stimulated platelets deficient in LAT spread nor-
mally on fibrinogen-coated surfaces. Together, these findings indicate that while LAT and
SLP-76 are equally required for signaling via the T cell antigen receptor (TCR) and pre-TCR,
platelet activation downstream of GPVI and 
 
 
 
IIb
 
 
 
3 shows a much greater dependency on
SLP-76 than LAT.
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Introduction
 
Adaptor proteins lack intrinsic effector functions, but con-
tain distinct modular domains which mediate protein–pro-
tein interactions. These molecules thus serve as the scaf-
folding around which effectors and their substrates are
assembled into signaling complexes (1). Two such hemato-
poietic cell–specific adapters are the Src homology 2
(SH2)
 
*
 
 domain-containing leukocyte phosphoprotein of
76 kD (SLP-76; reference 2), and linker for activation of T
cells (LAT; reference 3). Expression of SLP-76 and LAT is
restricted to T cells, NK cells, macrophages, mast cells, and
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Abbreviations used in this paper:
 
 CRP, collagen-related peptide; Cvx, con-
vulxin; GEM, glycolipid-enriched membrane microdomain; GFP, green
fluorescent protein; LAT, linker for activation of T cells; Rag, recombi-
nation activating gene; SEM, scanning electron microscopy; SH2, Src ho-
mology 2; SLP-76, SH2 domain-containing leukocyte phosphoprotein of
76 kD. 
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megakaryocyte-lineage cells (2, 4, 5). SLP-76 is composed
of three modular domains including an NH
 
2
 
-terminal
acidic region which contains key tyrosine residues (2), a
central proline-rich region and a COOH-terminal SH2
domain. Tyrosine residues within the acidic region of SLP-
76 become phosphorylated after TCR ligation (6, 7), and
then bind the guanine nucleotide exchange factor, Vav (8–
11), the adaptor, Nck (12), and the Tec family kinase, Itk
(13–15). In vivo reconstitution studies have demonstrated
that the NH
 
2
 
-terminal tyrosines are critical for normal T
cell development and TCR function (16), however, which
of these intermolecular interactions are most critical for
these events remains to be determined. The SH2 domain
of SLP-76 binds to the SLP-76–associated phosphoprotein
of 130 kD, SLAP-130/FYB (17, 18). SLAP-130/FYB is
also an adaptor molecule and has been implicated in prolif-
eration and integrin function in T cells (19, 20), and has
been shown to colocalize and associate with vasodilatator-
stimulated phosphoprotein (VASP) in platelets (21, 22).
The central proline-rich region of SLP-76 is required for
constitutive association with the Grb-2 family member
Gads (23–25). After antigen recognition by the TCR, Gads
associates with LAT bringing SLP-76 to the membrane and
localizing it to glycolipid-enriched membrane micro-
domains (GEMs) (26, 27), specialized regions within the
membrane in which signal transduction complexes are
formed (28). GEMs can also be isolated from platelets,
where their role is under investigation (29).
The transmembrane adaptor LAT is a 36-kD protein
which is resident in GEMs due to palmitylation of two
conserved cysteine residues (26). Within the cytoplasmic
domain of LAT are six tyrosine residues which in T cells
become phosphorylated after activation of the Syk family
member ZAP-70. These phosphorylated tyrosines are criti-
cal for T cell activation (30, 31) and mediate protein–pro-
tein interactions with multiple proteins including Gads,
Grb2, PI3K, and PLC
 
 
 
1 (3, 23–25). In platelets, LAT is
part of a large signaling complex and coprecipitates with
SLP-76, PLC
 
 
 
2, Cbl, Grb2, Gads, and Src kinase–associ-
ated phosphoprotein homologue (SKAP-HOM) (32).
Much has been learned about the functions of SLP-76
and LAT through analysis of mice made deficient for either
molecule. SLP-76–null mice lack peripheral T cells (33,
34) and have reduced viability associated with perinatal
hemorrhage (35). In addition, platelets from SLP-76
 
 
 
/
 
 
 
animals fail to phosphorylate PLC
 
 
 
2 or aggregate in re-
sponse to collagen (35, 36), and show a defect in spreading
downstream of the fibrinogen receptor, integrin 
 
 
 
IIb
 
 
 
3
(37). LAT-deficient mice also lack T cells; however, they
are born at expected frequencies and show no signs of
bleeding (38). We have shown previously that LAT
 
 
 
/
 
 
 
platelets have impaired responses to collagen-related pep-
tide (CRP), including decreased PLC
 
 
 
2 phosphorylation
and granule release (39).
As SLP-76 and LAT inducibly associate via a third adap-
tor, Gads (23–25), and mice null for each of these proteins
exhibit defects in T cell development and activation (33,
34, 38, 40), we next asked if these molecules function co-
ordinately and are each required similarly for T cell versus
platelet activation. Using biochemical and genetic ap-
proaches, we show that, in contrast to SLP-76, LAT is dis-
pensable for platelet aggregation in response to high con-
centrations of GPVI collagen receptor agonists and for
platelet spreading on the 
 
 
 
IIb
 
 
 
3 ligand, fibrinogen. Fur-
thermore, while the phosphorylated tyrosine residues of
SLP-76 are critical for both T cell development and platelet
activation, the Gads binding domain is dispensable for
platelet spreading on fibrinogen, but important for platelet
granule release and normal T cell development.
 
Materials and Methods
 
Antibodies, Reagents, and Mice.
 
Anti–P-selectin was from BD
PharMingen and anti-PLC
 
 
 
2 was from Santa Cruz Biotechnol-
ogy, Inc. Purified human fibrinogen and 
 
 
 
-thrombin were from
Enzyme Research Laboratories, and collagen from Chronolog
Corp. Purified convulxin (Cvx) from the venom of 
 
Crotalus duris-
sus terrificus
 
 was the gift of Mark Kahn (University of Pennsylva-
nia; reference 41). CRP (GKP
 
*
 
(GPP)
 
10
 
GKP
 
*
 
G, where P repre-
sents hydroxyproline) was cross-linked via lysine residues as
described previously (42). LAT-deficient mice (38) were the gift
of Larry Samelson (National Institutes of Health, Bethesda, MD).
SLP-76–deficient mice have been described previously (31) as
have Gads-deficient mice (40). SLP-76–, LAT-, and Gads-defi-
cient mice were housed under pathogen-free conditions at the
University of Pennsylvania or the Washington University Animal
Care Facilities under National Institutes of Health guidelines and
approved animal protocols. Recombinant hematopoietic growth
factors were from R&D Systems.
 
Platelet Isolation.
 
Whole blood was obtained from mice by
cardiac puncture and anticoagulated with 0.1 vol acidic-citrate-
dextrose. 4 ml of Pipes-Saline buffer (150 mM NaCl, 20 mM
PIPES, pH 6.5) were added and platelet-rich plasma (PRP) was
obtained by centrifugation at 200 
 
g
 
 for 20 min at 25
 
 
 
C. Washed
platelets were then obtained by adding apyrase (1 U/ml final con-
centration) and prostaglandin E1 (1 
 
 
 
M), centrifuging at 600 
 
g
 
for 20 min at 25
 
 
 
C, and resuspending the platelet pellet in a mod-
ified Tyrode’s buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM
Na
 
2
 
HPO
 
4
 
-12H
 
2
 
O, 12 mM NaHCO
 
3
 
, 20 mM HEPES, 1 mM
MgCl
 
2
 
, 5 mM glucose, pH 7.35). Human whole blood was ob-
tained from medication-free volunteers and washed platelets were
prepared as described (43).
 
Aggregation, Immunoprecipitation, and Western Blotting.
 
Washed
murine platelets were resuspended to a concentration of 4 
 
 
 
 10
 
8
 
/
ml in a volume of 250 
 
 
 
l modified Tyrode’s buffer. Aggregation
was assayed using a Chronolog aggregometer to measure light
transmission. After a 3-min aggregation period, platelets were
lysed using 2
 
  
 
NP-40 buffer including inhibitors of proteases (50
 
 
 
g/ml aprotinin, 10 
 
 
 
g/ml leupeptin, 50 
 
 
 
g/ml pepstatin A, and
1 mM pefablock) and phosphatases (400 
 
 
 
M sodium vanadate, 10
mM sodium fluoride, and 10 mM sodium pyrophosphate). Clari-
fied lysates were subjected to immunoprecipitation with anti–
human LAT, immunoprecipitates were probed on Western blots
with anti-phosphotyrosine mAbs, 4G10 (Upstate Biotechnology)
and PY20 (Transduction Laboratories), and immunoreactive
bands were detected by enhanced chemiluminescence (ECL;
Amersham Pharmacia Biotech).
For human platelet studies, bacterial Petri dishes were coated
overnight at 4
 
 
 
C with 100 
 
 
 
g/ml fibrinogen or 5 mg/ml BSA in
coating buffer (150 mM NaCl, 50 mM NaH
 
2
 
PO
 
4
 
, 50 mM 
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Na
 
2
 
HPO
 
4
 
, pH 8.0), followed by blocking in 5 mg/ml BSA for
2 h at room temperature. Platelet adhesion to fibrinogen was per-
formed by adding washed platelets (10
 
8
 
 platelets/ml) to the dishes
or coverslips for 30 min at 37
 
 
 
C. After removing nonadherent
platelets from the fibrinogen-coated Petri dishes with three
washes of PBS, adherent platelets were lysed for 30 min on ice in
1% RIPA lysis buffer including inhibitors of proteases and phos-
phatases. Platelets incubated in BSA-coated dishes served as sus-
pension controls and were pelleted for 5 s at 16,000 
 
g
 
 before lysis.
Clarified lysates were subjected to immunoprecipitation with
anti–human SLP-76(44) or anti–human LAT (Upstate Biotech-
nology), immunoprecipitates were probed on Western blots with
anti-phosphotyrosine mAbs.
 
Confocal Microscopy and Scanning Electron Microscopy.
 
Washed
platelets were allowed to adhere to fibrinogen-coated coverslips
for 45 min at 37
 
 
 
C. Coverslips were then washed and platelets
fixed in 1% gluteraldehyde for scanning electron microscopy
(SEM) or 3.7% formaldehyde followed by 1% Trition for confo-
cal microscopy. Coverslips for SEM were dehydrated and sput-
ter-coated with gold followed by analysis using an Hitachi
S-4000 (University of Iowa Microscopy Facility). Coverslips for
confocal microscopy were stained with 4G10 and PY20, Cy5-
anti–mouse IgG and rhodamine-phalloidin, and confocal micros-
copy was performed as described (43).
 
Flow Cytometry.
 
Washed murine platelets (10
 
6
 
) were stimu-
lated with 0.5 U/ml human 
 
 
 
-thrombin, 40 or 10 nM Cvx, 40
or 20 
 
 
 
g/ml CRP in the presence of 5 
 
 
 
g/ml FITC anti-murine
P-selectin or biotinylated anti-murine P-selectin along with
streptavadin-allophycocyanin (APC), and binding was quantified
by flow cytometry.
 
Genetic Reconstitution of SLP-76–deficient Bone Marrow.
 
A 1.6-
kb murine SLP-76 cDNA was cloned into the BglII site of the
MigR1 vector (45). This BglII site lies directly 5
 
 
 
 of an internal
ribosome entry site (IRES) which is followed by a cDNA coding
for enhanced green fluorescent protein (GFP). Bosc23 cells were
transfected with MIGR1 and viral supernatants were collected as
described (46). Bone marrow cells were harvested from the tibias
and femurs of SLP-76–deficient mice and cultured for 4 d at a
density of 2 
 
 
 
 10
 
6
 
 cells/ml in the presence of 6 ng/ml rmIL-3,
10 ng/ml rmIL-6, and 50 ng/ml rmSCF in DMEM containing
15% fetal calf serum and 5% WEHI-conditioned medium. At 24
and 48 h, cells were spin infected with retroviral supernatants
followed by intravenous injection into lethally irradiated 4 to
6-wk-old C57/BL6 or RAG2
 
 
 
/
 
 
 
 recipients as described (45).
Mice were killed and tissues harvested for analysis 6–8 wk after
reconstitution.
 
Results
 
LAT
 
 
 
/
 
 
 
 Platelets Aggregate in Response to High Concentra-
tions of Collagen.
 
The differential requirement of SLP-76
and LAT for hemostasis led us to further assess the roles of
these molecules in platelet function. Previously we have
shown that platelets from LAT
 
 
 
/
 
 
 
 mice exhibit a marked
reduction in both surface expression of P-selectin and
phosphorylation of PLC
 
 
 
2 in response to CRP (39). We
therefore asked whether LAT-deficient platelets can re-
spond to a more physiologic agonist, collagen. Surprisingly,
aggregation in response to 30 
 
 
 
g/ml collagen occurs simi-
larly in platelets from LAT
 
 
 
/
 
 
 
 and LAT
 
 
 
/
 
 
 
 mice (Fig. 1 B).
In comparison, SLP-76–deficient platelets exhibit only
minimal responses to this high concentration of collagen.
Because limited amounts of material precluded a direct as-
sessment of PLC
 
 
 
2 function in response to collagen recep-
tor ligation, we next examined inducible tyrosine phos-
phorylation of PLC
 
 
 
2 which has been linked to its
enzymatic activation. After a 3-min aggregation period,
platelets were lysed and PLC
 
 
 
2 was immunoprecipitated.
Immune complexes were then separated by SDS-PAGE,
transferred to nitrocellulose and blotted with anti-phospho-
tyrosine antibodies. As shown, LAT deficiency results in a
modest reduction of PLC
 
 
 
2 phosphorylation when plate-
lets are treated with 30 
 
 
 
g/ml collagen, even though
LAT
 
 
 
/
 
 
 
 platelets aggregate fully (Fig. 1 B). However, in
the absence of SLP-76 there is a marked decrease in PLC
 
 
 
2
tyrosine phosphorylation levels compared with that seen in
SLP-76
 
 
 
/
 
 
 
 platelets.
Because collagen is known to bind multiple surface re-
ceptors (47), we investigated whether the response of
LAT-deficient platelets to high concentrations of collagen
is due to signal transduction events occurring downstream
of GPVI or through another collagen receptor. When acti-
vated with 10 nM of the potent GPVI-selective agonist,
Cvx, there is intermediate aggregation and PLC
 
 
 
2 phos-
phorylation in the absence of LAT, but no apparent re-
sponse by either measure in the absence of SLP-76 (Fig. 1
C). A higher concentration of Cvx (40 nM) induces aggre-
gation of LAT
 
 
 
/
 
 
 
 platelets similarly to LAT
 
 
 
/
 
 
 
 platelets
(Fig. 1 D). At this dose, SLP-76
 
 
 
/
 
 
 
 platelets also aggregate,
however, to a far lesser degree than LAT
 
 
 
/
 
 
 
 or LAT
 
 
 
/
 
 
 
cells. Similar to results seen with 30 
 
 
 
g/ml collagen, the
degree of PLC
 
 
 
2 phosphorylation is slightly reduced in
platelets deficient for LAT, while SLP-76–deficient plate-
lets reveal a marked diminution in PLC
 
 
 
2 phosphoryla-
tion (33).
A relatively low concentration (2 
 
 
 
g/ml) of CRP in-
duces a moderate aggregation response in LAT
 
 
 
/
 
 
 
 plate-
lets, but no detectable response in SLP-76
 
 
 
/
 
 
 
 platelets (Fig.
1 E). This correlates with a modest increase in PLC
 
 
 
2
phosphorylation in platelets deficient for LAT, and no de-
tectable PLC
 
 
 
2 phosphorylation in platelets deficient for
SLP-76. When stimulated with 4 
 
 
 
g/ml CRP, platelets
from SLP-76–null animals fail to aggregate or inducibly
phosphorylate PLC
 
 
 
2 while LAT
 
 
 
/
 
 
 
 platelets aggregate
fully and exhibit increases in PLC
 
 
 
2 phosphorylation (Fig.
1 F). It should be noted that the response to CRP appears
to depend heavily on assay conditions, as we have found
previously that under other activation conditions, CRP is a
poor agonist for PLC
 
 
 
2 phosphorylation and activation in
LAT-deficient platelets compared with wild-type (39).
The different results from our two studies are likely attrib-
utable to differences in stimulation conditions (in the pre-
vious work platelets were not stirred) reinforcing the no-
tion that in the absence of LAT, more potent GPVI
engagement is required for platelet activation. Together,
these data demonstrate that unlike SLP-76–deficient plate-
lets which manifest severe signaling defects after GPVI en-
gagement, there is only a partial defect in these signaling
pathways in LAT-null platelets. 
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Dose-dependent Responses of LAT
 
 
 
/
 
 
 
 Platelets to Col-
lagen.
 
Because platelets from LAT-deficient mice aggre-
gate in response to 30 
 
 
 
g/ml collagen but do not undergo
efficient granule release in response to CRP, we next asked
if this was due to the different agonists used or to intrinsic
differences in aggregation and release responses to collagen.
To address this, the responses of LAT-deficient and normal
platelets were compared over a range of collagen concen-
trations. At the lowest concentration of collagen tested (2
 
 
 
g/ml), LAT
 
 
 
/
 
 
 
 platelets fail to aggregate (Fig. 2 B). Con-
centrations of collagen greater than or equal to 4 
 
 
 
g/ml in-
duce aggregation of LAT
 
 
 
/
 
 
 
 platelets (Fig. 2 C) and aggre-
gation is nearly normal at 10 
 
 
 
g/ml collagen (Fig. 2 D); a
dose which results in no response in SLP-76
 
 
 
/
 
 
 
 platelets
(data not shown). After the 3-min aggregation period,
platelets were lysed and PLC
 
 
 
2 was immunoprecipitated
followed by Western blotting with anti-phosphotyrosine
antibodies. Western analysis revealed that at high concen-
trations of collagen, PLC
 
 
 
2 is heavily phosphorylated in
LAT
 
 
 
/
 
 
 
 platelets, while at concentrations less than 5 
 
 
 
g/
ml phosphorylation of PLC
 
 
 
2 is significantly diminished.
These data are consistent with a strength of signal model in
which LAT modulates signal transduction events after col-
lagen binding, but can be bypassed when platelets are acti-
vated with high concentrations of agonist.
 
P-selectin Upregulation Is Reduced in Platelets from LAT-defi-
cient Mice and Absent in Platelets from SLP-76–deficient
Mice.
 
P-selectin expression at the platelet surface is a
marker of platelet 
 
 
 
-granule release. Due to the aggrega-
tion response of LAT-deficient platelets, we next asked if
Figure 1. LAT /  platelets, but not SLP-76 /  plate-
lets, aggregate normally in response to potent GPVI ago-
nists. Platelets isolated from either, LAT / SLP / ,
LAT / SLP / , or LAT / SLP /  mice were (A) left un-
stimulated or stimulated (arrows) with (B) 30  g/ml collagen,
(C) 10 nM Cvx, (D) 40 nM Cvx, (E) 2  g/ml CRP, or (F)
4  g/ml CRP for 3 min with stirring in an aggregometer.
Platelets were then lysed and PLC 2 was immunoprecipi-
tated followed by Western analysis for phosphotyrosine.
Blots were stripped and reprobed with anti-murine PLC 2. 
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LAT
 
 
 
/
 
 
 
 platelets undergo granule release normally in re-
sponse to high concentrations of CRP and Cvx. Platelets
from LAT
 
 
 
/
 
 
 
, LAT
 
 
 
/
 
 
 
, and SLP-76
 
 
 
/
 
 
 
 mice express P-selec-
tin in response to the G-protein–coupled receptor agonist,
thrombin. In addition, platelets from LAT heterozygous
littermates responded normally to Cvx and CRP, with as
many as 42% of the platelets expressing P-selectin on their
surface in response to 40nM Cvx (Fig. 3). In contrast, only
8% of LAT
 
 
 
/
 
 
 
 platelets respond to the highest concentra-
tion of Cvx, a dose which induces full platelet aggregation.
Also as shown, LAT-deficient platelets exhibit defective re-
sponses to both 10 and 20 
 
 
 
g/ml CRP. SLP-76
 
 
 
/
 
  plate-
lets fail to inducibly express P-selectin in response to both
GPVI agonists. These results confirm that both LAT and
SLP-76 are required for optimal granule release. Thus, it is
possible that the aggregation defect with low concentra-
tions of GPVI agonists observed in the LAT-deficient mice
relates to defective release of positive feedback stimuli such
as ADP from platelet granules.
Differential Requirement for SLP-76 and LAT Downstream
of  IIb 3 Engagement. We have shown that in addition to
defects in collagen signaling, SLP-76 /  platelets exhibit
defects in outside-in signaling downstream of integrin
 IIb 3. Because both SLP-76 and Syk are inducibly phos-
phorylated after fibrinogen binding to  IIb 3 (22, 37, 48),
we asked if LAT plays a role in this pathway. Washed hu-
Figure 2. LAT is required for optimal platelet activation in response to collagen. Washed murine platelets where analyzed for aggregation responses to
either (A) no stimulus (B) 2  g/ml, (C) 4  g/ml, (D) 10  g/ml, or (E) 30  g/ml collagen (arrows). After stimulation for 3 min, LAT /  and LAT / 
platelets were lysed and PLC 2 and SLP-76 were sequentially immunoprecipitated followed by Western analysis for phosphotyrosine. Blots were then
stripped and reprobed for either PLC 2 or SLP-76.
Figure 3. P-selectin upregulation is reduced in
LAT /   platelets and absent in SLP-76 /   platelets.
Washed murine platelets were stimulated with 0.5 U/ml
thrombin, 40 nM Cvx, 10 nM Cvx, 20  g/ml CRP, or
10  g/ml CRP for 10 min at 37 C in the presence of
FITC- -P-selectin followed by fixation and flow cyto-
metric analysis. Results were then plotted as the percent
of platelets staining positive for P-selectin.710 Differential Requirement for SLP-76 and LAT in Platelet Activation
man platelets were incubated on Petri plates coated with
BSA, fibrinogen, or Cvx for 30 min at 37 C. As expected,
nonadherent platelets incubated on BSA-coated plates do
not exhibit tyrosine phosphorylation of either LAT or
SLP-76. As we have shown previously, platelets adherent
to fibrinogen manifest SLP-76 phosphorylation (22, 37).
Surprisingly, there is no detectable tyrosine phosphoryla-
tion of LAT (Fig. 4 A), although both molecules are induc-
ibly phosphorylated when platelets adhere to the GPVI
ligand, Cvx. Consistent with these findings, LAT-deficient
platelets activated with collagen spread normally on fibrin-
ogen coated coverslips (Fig. 4 B). These data demonstrate
that in addition to a LAT-independent signaling pathway
downstream of GPVI, outside-in signaling through integrin
 IIb 3 can occur in the absence of this adaptor.
Retroviral Rescue of SLP-76–deficient Mice. The forma-
tion of a SLP-76/LAT complex has been shown to be crit-
ical for integration of signals initiated by the TCR (49). In
T cells, SLP-76 binds constitutively to Gads which, in turn
inducibly associates with LAT resulting in GEM localiza-
tion of the signaling complex (27). Recently (16), we have
found that transgenic reconstitution of SLP-76–deficient
thymocytes with wild-type SLP-76 rescues T cell develop-
ment and function, whereas expression of a mutant variant
of SLP-76 which cannot be phosphorylated on tyrosine
residues fails to rescue these events. Expression of a mutant
SLP-76 which cannot bind Gads results in delayed thy-
mocyte development and severe defects in TCR signaling
in peripheral T cells underscoring the importance of the
SLP-76/Gads interaction for T cell function. However,
given our findings that platelet activation appears to differ-
entially require SLP-76 and LAT, we wondered if forma-
tion of the SLP-76/Gads/LAT complex is as important for
platelet function as it appears to be for T cells.
As the transgenic constructs are not expressed in plate-
lets, we used a retroviral reconstitution system to study the
structure/function relationships of SLP-76 in this lineage.
The retroviral system makes use of an IRES for expression
of the marker gene, GFP, and the gene of interest from the
same transcript. Four viral constructs were used to trans-
duce SLP-76–deficient bone marrow: GFP alone (MigR1),
full length murine SLP-76 (WT-SLP-76), SLP-76 in
which each of the three critical tyrosine residues have been
mutated to phenylalanine (Y3F-SLP-76), and SLP-76
Figure 4. LAT /  platelets spread in response to collagen and fibrinogen. (A) Washed human platelets were incubated for 30 min at 37 C on Petri
dishes coated with 5 mg/ml BSA, 100  g/ml fibrinogen (FIB), or 1  g/ml Cvx. Nonadherent platelets were isolated by centrifugation (5 s, 16,000 g)
and then lysed with RIPA buffer (BSA condition). Fibrinogen or Cvx-adherent platelets were lysed directly on the Petri dishes. Equal amounts of protein
from each lysate were subjected to immunoprecipitation (IP) with anti–human SLP-76 or anti–human LAT followed by Western analysis for phosphoty-
rosine. Blots were reprobed with anti-human SLP-76 or LAT to demonstrate equal loading. WB, Western blot. (B) Washed LAT /  or LAT /  plate-
lets were incubated on coverslips coated with 100  g/ml fibrinogen. Cells were stimulated with 30  g/ml collagen for 45 min at 37 C followed by fix-
ation and analysis by SEM. Each image is  5,000.711 Judd et al.
which cannot bind to Gads ( 224–244-SLP-76) (Fig. 5 A).
Lethally irradiated recombination activating gene (Rag)2 / 
mice were reconstituted with the retrovirally transduced
SLP-76 /  bone marrow and  6 wk later, mice were
killed and tissues harvested for study.
As a proof of principle, we first examined thymocyte de-
velopment in the reconstituted mice (Fig. 5 B) and found
that this readout in the transplanted mice is consistent with
our findings using the T cell–specific transgenes. As shown,
infection of SLP-76–deficient bone marrow with retrovirus
encoding GFP alone (MigR1) fails completely to restore
thymocyte development, while reconstitution by WT-SLP-
76 rescues T cell development with restored thymic cellular-
ity and the appearance of double-positive as well as CD4
and CD8 single-positive cells. The success of thymocyte de-
velopment (as evidenced by the number of single-positive
cells) in the wild-type SLP-76 restored mice varies, but is al-
ways at least as efficient as seen after transfer of wild-type
bone marrow. This is likely due to levels of SLP-76
achieved after retroviral infection, similar to what we have
observed previously following rescue with SLP-76 trans-
genes (16). The data in Fig. 5 B demonstrate also that muta-
tion of the three critical tyrosine residues within the NH2
terminus of SLP-76 (Y3F-SLP-76) results in a profound de-
crease in both double- and single-positive cells. Deletion of
the Gads binding domain ( 224–244-SLP-76) results in an
intermediate phenotype, also manifesting severe abnormali-
ties in T cell developmental progression. The T cell pheno-
types observed with the mutant variants of SLP-76 intro-
duced by retroviral infection are also consistent with what
Figure 5. Structure/function
analysis of SLP-76 by retroviral
reconstitution. (A) Retroviral
constructs used for coexpression
of SLP-76 and GFP in trans-
duced SLP-76 /  hematopoi-
etic cells. Virus expressing GFP
alone (MigR1), or GFP with
WT-SLP-76, SLP-76 which
cannot be tyrosine phosphory-
lated (Y3F-SLP-76), or SLP-76
which cannot bind Gads ( 224–
244-SLP-76) were used to trans-
duce SLP-76–deficient stem cells
followed by transfer to lethally
irradiated Rag2 /  hosts. After
 6 wk, mice were killed and
tissues harvested for analysis. (B)
Thymocytes were removed from
the reconstituted mice, fixed,
and stained for CD4 and CD8
followed by flow cytometric
analysis. In the top two panels all
thymocytes (All) from a nonma-
nipulated C57/Bl6 (a normal thymic profile) and Rag2 /  (a profile from mice deficient for T cells) mouse were analyzed. For retrovirally reconstituted
mice, gates were set to distinguish GFP-positive cells (GFP) which were then analyzed for CD4 and CD8 expression. Numbers indicate the percentage
of cells in each quadrant.712 Differential Requirement for SLP-76 and LAT in Platelet Activation
Figure 6 (continues on facing page)713 Judd et al.
we found using the transgenic approach (16), further validat-
ing the use of retroviral reconstitution to examine the struc-
ture/function relationships of SLP-76 in various hematopoi-
etic lineages, including platelets.
The Role of the Gads Binding Region of SLP-76 in Platelet
Function. Platelets harvested from retrovirally reconsti-
tuted mice described for Fig. 5 B were stimulated with 40
nM Cvx for 10 min. Cells were then assessed for expression
of P-selectin by flow cytometry. Gates were set to distin-
guish GFP-positive (transduced) from GFP-negative (non-
transduced) cells and results were then plotted as the per-
centage of platelets staining positive for P-selectin (Fig. 6
A). As shown previously, WT-SLP-76 reconstitutes P-selec-
tin release in response to 40 nM Cvx to levels near that of
the RAG2 /  control platelets while both nontransduced
(GFP-negative) cells and cells transduced with GFP alone
(MigR1) do not respond to Cvx (32). In contrast to WT-
SLP-76, Y3F-SLP-76 consistently fails completely to recon-
stitute P-selectin expression suggesting that the NH2-termi-
nal tyrosine residues of SLP-76 are required for granule
release. Platelets expressing the Gads binding mutant of
SLP-76 ( 224–244-SLP-76) exhibit an intermediate, but
variable, response to Cvx in comparison to rescue with
wild-type SLP-76. On average, cells expressing the Gads
binding mutant responded  60% as well as those infected
with WT-SLP-76 (n   6). Interestingly, although wild-type
responses are not achieved, platelets expressing the  224–
244-SLP-76 mutation always demonstrate increased induc-
ible P-selectin expression when compared with LAT / 
cells, suggesting an alternative, albeit inefficient, means by
which this SLP-76 mutant may be recruited to LAT and
GEMs. Alternatively, it is possible that GPVI may signal
through SLP-76 and LAT leading to granule release even
when the two adapters do not physically interact.
Our findings indicating that the Gads binding domain of
SLP-76 is not essential for rescue of Cvx-mediated granule
release suggests the possibility that signaling via GPVI may
not require Gads. We tested this hypothesis directly using
mice deficient in this adaptor protein. Platelets from Gads-
deficient mice, which show significant defects in T cell
maturation and function (40), were stimulated with 40 and
20 nM Cvx followed by flow cytometric analysis of
P-selectin surface expression. In contrast to LAT-deficient
platelets, platelets lacking Gads undergo granule release
normally (Fig. 6 C). The absence of a defect in the Gads / 
cells may be due to the ability of Grb2 to bind SLP-76, an
interaction which has been shown to occur in vitro and is
mediated by amino acids 224–244 of SLP-76 (44), and sub-
sequently bring SLP-76 to LAT.
Given that LAT-deficient platelets spread efficiently fol-
lowing collagen and fibrinogen receptor engagement (Fig.
4 B), we predicted that the Gads binding region of SLP-76
would be dispensable for this platelet response. To test this
directly, platelets from reconstituted mice were analyzed by
confocal microscopy (Fig. 6 B). Platelets deficient for SLP-
76 (GFP-negative cells and MigR1-transduced cells) fail to
spread under these conditions, while reconstitution of SLP-
76 expression (WT-SLP-76) restores platelet spreading.
The phosphorylated tyrosine residues of SLP-76 are critical
for this response as Y3F-SLP-76 transduced cells fail to
spread. Consistent with our finding that LAT-deficient cells
can respond to high concentrations of collagen and trans-
duce outside-in signals through  IIb 3 (Fig. 4), the  224–
244-SLP-76 mutant restores platelet spreading similarly to
WT-SLP-76. This finding indicates that although SLP-76
and its NH2-terminal tyrosines are critical for platelet
spreading, this aspect of platelet function does not depend
on a trimolecular interaction between SLP-76/Gads/LAT
(nor solely the interaction between Gads and SLP-76).
Discussion
The adaptor molecules SLP-76 and LAT have overlap-
ping expression patterns and appear to function coordi-
Figure 6. Structure/function analysis of SLP-76 in
platelets. (A) Retrovirally transduced or nonmanipulated
Rag2 /  platelets were either left unstimulated, stimu-
lated with thrombin, or Cvx for 10 min in the presence of
 -P-selectin followed by fixation and analysis by flow cy-
tometry with gates set to distinguish GFP-positive cells
from GFP-negative cells. Results were then plotted as the
percent of platelets staining positive for P-selectin. (B)
Washed platelets were incubated on coverslips coated with
100  g/ml fibrinogen in the presence of 30 mg/ml collagen
for 45 min. Cells were fixed, permeabilized, and then
stained for phosphotyrosine (blue) and F-actin (red). Arrows
indicate GFP-positive cells. The bar in the lower right cor-
ner corresponds to 10  m. (C) Washed murine platelets
from wild-type (WT), LAT / , or Gads /  were stimu-
lated with 0.5 U/ml thrombin, 40 nM Cvx, or 20 nM Cvx
for 10 min at 37 C in the presence of FITC- -P-selectin
followed by fixation and flow cytometric analysis. Results
were then plotted as the percent of platelets staining posi-
tive for P-selectin.714 Differential Requirement for SLP-76 and LAT in Platelet Activation
nately in T cell activation. Both molecules are similarly re-
quired for signal transduction after TCR ligation and
during T cell development (33, 34, 38). In addition to a
similar phenotype in the T cell compartment, mice made
deficient for either SLP-76 or LAT manifest mast cell sig-
naling defects (50, 51). Furthermore, in contrast to LAT-
deficient mice, SLP-76–null animals have a bleeding di-
athesis and decreased perinatal survival (34, 35). This
contrast in phenotypes argues that SLP-76 is required in
pathways in which LAT is not. To further explore this is-
sue, we have now expanded our studies of both LAT-defi-
cient and SLP-76–deficient platelets.
Previously we have shown that platelets from LAT / 
mice exhibit reduced P-selectin surface expression, and
 IIb 3 activation in response to CRP (39). In the current
report we confirm defective signaling to this agonist and
find further that the failure to express normal levels of
P-selectin is not overcome at higher concentrations of
CRP or after stimulation with the more powerful GPVI
agonist, Cvx. Surprisingly, however, we find that LAT-
deficient platelets phosphorylate PLC 2 and aggregate fully
in response to high concentrations of collagen, Cvx or
CRP. This observation suggests a model in which GPVI-
mediated granule release can be uncoupled from platelet
aggregation. Our observation that at lower concentrations
of collagen, CRP, and Cvx there is an aggregation defect
of the LAT-deficient cells reinforces the notion that a com-
plete response to less potent GPVI engagement requires ef-
ficient granule release.
Our current studies also indicate that although expressed
in both platelets and T cells, mechanisms of action of SLP-
76 and LAT do not overlap completely in the two cell
types. First, we found that while engagement of the fibrin-
ogen receptor,  IIb 3, results in tyrosine phosphorylation
of SLP-76, there is no similar change detectable in LAT.
Consistent with this, when stimulated with collagen and al-
lowed to adhere to a fibrinogen matrix, LAT-deficient cells
spread normally whereas SLP-76–deficient platelets fail to
spread under these conditions (37). Collectively, our stud-
ies comparing SLP-76– and LAT–deficient platelets suggest
that the interaction between SLP-76 and LAT (mediated
by the adaptor protein, Gads), while essential for TCR sig-
naling, is dispensable for platelet spreading in response to
collagen and fibrinogen binding (Fig. 7). We tested this hy-
pothesis further by reconstituting SLP-76 deficient platelets
with wild-type or mutant variants of the adaptor.
As shown, retroviral reconstitution of WT-SLP-76 re-
stores T cell development as well as platelet function in re-
sponse to collagen and fibrinogen. In contrast, reconstitu-
tion with a mutant variant of SLP-76 incapable of
becoming tyrosine phosphorylated (Y3F-SLP-76) results in
a severe block in T cell development, and in granule re-
lease and spreading in cells expressing this mutant. These
data suggest that some of the protein–protein interactions
mediated by SLP-76 are similarly required for T cell and
platelet function. We speculate that the binding and re-
cruitment of Vav may play a critical role in this process.
Analysis of mice deficient in expression of multiple Vav
Figure 7. Differential roles for the SLP-76/Gads/LAT axis in T cells versus
platelets. (A) A critical event during T cell activation is the recruitment of SLP-76
to LAT. SLP-76 constitutively binds Gads which, upon T cell activation, inducibly
associates with LAT. All three molecules are required for T cell development and
activation. (B) In platelets, SLP-76 can work independently of its association with
LAT to mediate signal transduction events downstream of  IIb 3. Furthermore,
while formation of a SLP-76/Gads/LAT complex is required for efficient granule
release and subsequent aggregation, strong stimulation of GPVI results in platelet
aggregation even in the absence of LAT. Therefore, at high concentrations of
collagen, granule release is not required to achieve efficient aggregation, however,
at weaker doses defective granule release by LAT-deficient platelets results in a
failure to aggregate.715 Judd et al.
isoforms will be required to address the importance of this
intermolecular relationship (52).
In contrast to the NH2-terminal tyrosines of SLP-76, we
found a differential requirement for the Gads binding re-
gion of SLP-76 in platelets versus T cells. Thus, mutation
of the Gads binding region of SLP-76 ( 224–244-SLP-76)
disrupts T cell development and function, however, plate-
let spreading in response to collagen and fibrinogen is nor-
mal with this mutant. The SLP-76 structure/function anal-
ysis is consistent with our observation that signaling via
integrin  IIb 3 involves phosphorylation of SLP-76 but
not LAT, suggesting the likelihood that the SLP-76/Gads/
LAT axis is not critical for  IIb 3 signal transduction (Fig.
7). It is likely that the ability of SLP-76 to couple to the
PLC  signaling cascade in the absence of association with
LAT is due to a direct interaction between the proline rich
region of SLP-76 (outside of the Gads binding site) and
PLC  (53). Importantly, in our transgenic reconstitution
studies we found that, although unable to bind Gads, the
 224–244-SLP-76 construct still binds to PLC  as well as
the other known SLP-76 interacting proteins (16).
Granule release in response to Cvx is rescued with the
 224–244 mutant of SLP-76, however, as predicted based
on the defects seen in the LAT /  platelets, the restoration
is not to wild-type levels. These data suggest, therefore,
that while in the absence of Gads binding to SLP-76 gran-
ule release can occur, maximal granule secretion in re-
sponse to GPVI agonists requires the Gads binding region
of SLP-76, likely to facilitate recruitment of SLP-76 and its
partner proteins to signaling complexes within the cell.
However, studies of Gads-deficient platelets indicate that
this adaptor is not critical for platelet granule release or ag-
gregation in response to several GPVI agonists (Fig. 6 C,
and results not shown). One plausible explanation for this is
that in the absence of Gads, association of SLP-76 with
LAT may occur through other known binders including
Grb2 (which associates with the same region of SLP-76 as
Gads) or PLC 2 (which associates with other residues
within the SLP-76 proline rich region [53]). Thus, in the
absence of the preferred in vitro SLP-76 binder, Gads,
Grb2, or another family member may substitute bringing
SLP-76 to LAT. However, it should be noted that in Gads-
deficient T cells, there is no evidence of increased Grb2 as-
sociation with SLP-76 (40), suggesting that either platelet
interactions differ from those seen in T cells or perhaps an-
other Grb2 family member may substitute in platelets. Ad-
ditionally, in the case of  224–244-SLP-76, which cannot
associate with Grb2 family members, LAT and SLP-76
may still form a complex mediated by yet other interacting
proteins (e.g. PLC 2). Further mutational analysis of SLP-
76 and its associated molecules will be required to deter-
mine if this is the case.
Signal transduction in platelets has been investigated ex-
tensively in recent years. Due to difficulties manipulating
platelets and the lack of an easily transfectable representa-
tive cell line, models of platelet signal transduction have
largely been based on known functions of key proteins in
other cell types, including lymphocytes. Because GPVI as-
sociates with the ITAM bearing Fc  chain and ligation of
this receptor leads to Syk activation, many parallels do exist
between this platelet signal transduction pathway and those
downstream of both the T and B cell antigen receptors.
Our studies of LAT and SLP-76 reinforce the notion that
there are many similarities in platelet and T cell activation.
It appears, however, that there are also important differ-
ences as LAT and SLP-76 seem to be differentially required
for platelet activation downstream of GPVI and  IIb 3.
Future studies using additional “knock-out” mice and tis-
sue-specific expression of signaling molecules in megakary-
ocytes and platelets will further elucidate the molecular
mechanisms unique to platelet activation. Finally, although
these studies provide further information about platelet sig-
naling in SLP-76– and LAT-deficient mice, it remains un-
clear how the signaling defects relate to the bleeding di-
athesis of the SLP-76–null animals. Further studies of these
and other genetically altered mice will be required to pro-
vide a complete explanation for this failure of hemostasis.
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